PMGC Inc. (ELAB)
NasdaqCM: ELAB
· Echtzeitkurs · USD
0.83
-0.04 (-4.60%)
Zum Schluss: Aug 18, 2026, 3:57 PM
PMGC Inc. (ELAB) Stock Price, Analysis & Data
-4.60% (1D)
| Geld | 0.61 |
| Marktkapitalisierung | 3.77 Mio |
| Umsatz (TTM) | 2.58 Mio |
| Nettogewinn (TTM) | -13.57 Mio |
| Beta | n/a |
| EPS (ttm) | -150.06 |
| KGV (TTM) | n/a |
| Forward-KGV | n/a |
| KBV (TTM) | 0.31 |
| KUV (TTM) | 1.46 |
| Earnings Date | n/a |
| Brief | 1.09 |
| Volumen | 192,210 |
| Ø Vol. (20D) | 2,847,680 |
| Eröffnung | 0.87 |
| Vortagesschluss | 0.87 |
| Tagesspanne | 0.82 - 0.88 |
| 52-Wk Range | 0.82 - 309.89 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über ELAB
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss tre...
Branche Biotechnology
Sektor Healthcare
IPO Datum Nov 21, 2023
Mitarbeiter 32
Börse NasdaqCM
Tickersymbol ELAB
Website https://pmgcholdings.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von PMGC 590.08K, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -7.75 Mio, ein Anstieg von 24.05 %.
Finanzberichte
